focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

Share Price Information for Deltex Medical (DEMG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.115
Bid: 0.11
Ask: 0.12
Change: 0.00 (0.00%)
Spread: 0.01 (9.091%)
Open: 0.115
High: 0.115
Low: 0.115
Prev. Close: 0.115
DEMG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Share Dealings

30 Mar 2009 16:46

RNS Number : 7448P
Deltex Medical Group PLC
30 March 2009
 



Deltex Medical Group plc

Directors' share dealings

30 March 2009 Deltex Medical Group plc ("Deltex Medical" or the "Company")the global leader in oesophageal Doppler monitoring ("ODM")announces that Julian Cazalet a non-executive Director, has today notified the Company that on 26 March 2009 he purchased 500,000 ordinary shares of 1p each in the Company ("Shares") at 8 pence per share. 

Following the above purchase, Julian Cazalet owns 1,750,000 ordinary shares representing 1.74 per cent. of the Company's issued share capital. 

The Company also received notification today from New England Partners Capital, that it had disposed of 2,285,714 Shares at pence per Share on 26 March 2009 and no longer has a notifiable interest. Edwin Snape, a non-executive Director both personally and through his role as a principal of Nexus Medical Partners, a Deltex Medical shareholder, now has an interest in 4,478,896 Shares, representing 4.46 per cent. of the Company's issued share capital. Edwin Snape is also a principal of New England Partners Capital, a venture capital fund which is in the process of being wound up.

For further information, please contact:- 

 

Deltex Medical Group plc 01243 774 837

Nigel Keen, Chairman   njk@deltexmedical.com

Andy Hill, Chief Executive ahill@deltexmedical.com  

Ewan Phillips, Finance Director  eap@deltexmedical.com

 

Nominated Adviser & Broker

Arden Partners plc 020 7398 1630

Chris Hardie chris.hardie@arden-partners.com

Matthew Armitt matthew.armitt@arden-partners.com  

Notes for Editors 

Deltex Medical manufactures and markets the CardioQ-ODM(TM) monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. 

Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier. 

 

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay. 

 

There are already over 1,600 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. Over 1,000 patients a week are treated using the CardioQ-ODM. In addition, there are currently approximately 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:- 

 

Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works 

Proved that the CardioQ-ODM works in a wide range of surgical procedures 

Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. 

The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSDLFISSUSELD
Date   Source Headline
25th Oct 20133:01 pmRNSHolding(s) in Company
23rd Oct 20137:00 amRNSAdditional Dedicated Trainer Hospital in USA
23rd Oct 20137:00 amRNSFDA approves CardioQ-ODM+
23rd Sep 20137:00 amRNSPrivate Investor Event
10th Sep 20137:00 amRNSInterim Results
8th Aug 20137:00 amRNSNotice of Results
1st Aug 20137:00 amRNSUS Authorities Publish ODM Payment Instructions
26th Jul 20133:02 pmRNSAdditional Listing
9th Jul 20139:00 amRNSPre-Close Update
4th Jul 20137:00 amRNSPositive Study from St Thomas's Hospital
25th Jun 201311:30 amRNSIssue of Equity
25th Jun 201311:10 amRNSDirector/PDMR Shareholding
24th Jun 20137:00 amRNSFDA submission completed for CardioQ-ODM+
19th Jun 20137:00 amRNSPremier Update: Successful Pilot Study
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
30th May 20137:00 amRNSClinical Guidelines for Anaesthetists in France
17th May 201310:25 amRNSDirector/PDMR Shareholding
1st May 20138:47 amRNSResult of AGM
30th Apr 20137:00 amRNSAGM Statement
24th Apr 20135:44 pmRNSHolding(s) in Company
23rd Apr 20138:51 amRNSHolding(s) in Company
12th Apr 20133:23 pmRNSDirector Shareholding and Additional Listing
12th Apr 201312:42 pmRNSDirector/PDMR Shareholding - Replacement
12th Apr 20137:00 amRNSDirector/PDMR Shareholding
10th Apr 20137:00 amRNSUS Govt body grants unique payment code for ODM
25th Mar 20137:00 amRNSFinal Results
18th Mar 20137:00 amRNSOutstanding Achievement Award
4th Feb 20131:42 pmRNSHolding(s) in Company
28th Jan 201310:06 amRNSHolding(s) in Company
23rd Jan 201312:39 pmRNSDirector/PDMR Shareholding
18th Jan 201311:20 amRNSPlacing to raise £2.5 million
8th Jan 20137:00 amRNSPre-close update
24th Dec 20127:00 amRNSNHS sets requirements for Fluid Management
10th Dec 20127:00 amRNSNew study supports the importance of ODM
29th Nov 20127:00 amRNSStudy reinforces CardioQ-ODM competitive advantage
31st Oct 20129:52 amRNSDirector/PDMR Shareholding
25th Oct 20124:47 pmRNSAdditional Listing
23rd Oct 20127:00 amRNSNHS South Innovation Plan
19th Oct 20127:00 amRNSEnhanced Recovery Update
10th Oct 20124:25 pmRNSGrant of options
10th Oct 20124:23 pmRNSIssue of Equity and TVR
19th Sep 20127:00 amRNSInterim Results
9th Aug 20128:23 amRNSHolding(s) in Company
6th Jul 20127:00 amRNSPre-close update on six months ended 30 June 2012
3rd Jul 20127:00 amRNSERP backs wide adoption of CardioQ-ODM
29th Jun 201210:13 amRNSDirector/PDMR Shareholding
22nd May 20124:54 pmRNSIssue of Equity
2nd May 20121:00 pmRNSResult of AGM
16th Apr 20129:35 amRNSHolding(s) in Company (Replacement to 10/04/12)
16th Apr 20129:23 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.